The panel will aid in the diagnosis of patients with respiratory symptoms in about an hour by differentiating SARS-CoV-2 from other bacterial and viral pathogens.
The Department of Health and Human Services selected the diagnostic test for development support through a streamlined process called an easy broad agency announcement.
The firm said that in a first phase of the contract it will focus on further development of its fever test that analyzes immune system gene expression patterns.
The firm is developing the test under a contract with the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority.
The organizations noted in a letter to HHS and FDA that they "believe the agency's actions may in fact inflict greater harm on patients and impede innovation."
